NCT02361086View on ClinicalTrials.gov

A Study to Evaluate Once-Daily Oral VT-464 in Patients With Castration-Resistant Prostate Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

December 31, 2017

Study Completion Date

June 30, 2018

Conditions
Castration-resistant Prostate CancerCRPC
Interventions
DRUG

VT-464: given orally once daily in 28 day cycles

VT-464: given orally once daily in 28 day cycles either 5 days or 7 days a week.

Trial Locations (5)

23502

Virginia Oncology Associates, Norfolk

27710

Duke University Medical Center, Durham

29572

Carolina Urologic Research Center, Myrtle Beach

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

68130

Urology Cancer Center, Omaha

Sponsors
All Listed Sponsors
lead

Innocrin Pharmaceutical

INDUSTRY